HTG Molecular Diagnostics’ (HTGM) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) in a research note released on Tuesday. They currently have a $6.00 target price on the medical research company’s stock.
A number of other equities analysts also recently weighed in on the company. ValuEngine upgraded HTG Molecular Diagnostics from a strong sell rating to a sell rating in a report on Friday, September 1st. Zacks Investment Research downgraded HTG Molecular Diagnostics from a hold rating to a sell rating in a report on Tuesday, August 15th. Finally, Rodman & Renshaw upped their target price on HTG Molecular Diagnostics from $4.50 to $6.00 and gave the company a buy rating in a report on Tuesday, May 16th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $5.75.
HTG Molecular Diagnostics (NASDAQ HTGM) opened at 1.95 on Tuesday. The firm’s market capitalization is $22.32 million. The firm’s 50-day moving average is $1.90 and its 200-day moving average is $2.55. HTG Molecular Diagnostics has a 12 month low of $1.20 and a 12 month high of $4.45.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.60). The company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.80 million. HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%. On average, equities research analysts expect that HTG Molecular Diagnostics will post ($2.29) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “HTG Molecular Diagnostics’ (HTGM) “Buy” Rating Reaffirmed at HC Wainwright” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/13/htg-molecular-diagnostics-htgm-buy-rating-reaffirmed-at-hc-wainwright.html.
In related news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $1.81, for a total value of $2,081,161.53. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold 1,659,998 shares of company stock worth $3,073,696 in the last 90 days. 7.60% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the stock. UBS Group AG acquired a new position in HTG Molecular Diagnostics in the first quarter worth approximately $137,000. Two Sigma Securities LLC acquired a new position in HTG Molecular Diagnostics in the first quarter worth approximately $150,000. Granahan Investment Management Inc. MA acquired a new position in HTG Molecular Diagnostics in the first quarter worth approximately $228,000. Finally, Vanguard Group Inc. increased its holdings in HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after buying an additional 37,841 shares during the last quarter. Hedge funds and other institutional investors own 21.67% of the company’s stock.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.